615
Participants
Start Date
July 27, 2016
Primary Completion Date
August 6, 2018
Study Completion Date
August 6, 2018
Alirocumab
Pharmaceutical form:solution Route of administration: subcutaneous
Placebo for alirocumab
Pharmaceutical form:solution Route of administration: subcutaneous
ezetimibe
Pharmaceutical form:capsule Route of administration: oral
placebo for ezetimibe
Pharmaceutical form:capsule Route of administration: oral
atorvastatin
Pharmaceutical form:tablet Route of administration: oral
rosuvastatin
Pharmaceutical form:tablet Route of administration: oral
simvastatin
Pharmaceutical form:tablet Route of administration: oral
Investigational Site Number 7640004, Bangkok
Investigational Site Number 7640002, Pratumwan
Investigational Site Number 7640003, Bangkok Noi
Investigational Site Number 7640001, Muang
Investigational Site Number 1560027, Beijing
Investigational Site Number 1560043, Beijing
Investigational Site Number 1560039, Beijing
Investigational Site Number 1560012, Beijing
Investigational Site Number 1560018, Beijing
Investigational Site Number 3560014, New Delhi
Investigational Site Number 1560009, Shenyang
Investigational Site Number 1560001, Shenyang
Investigational Site Number 1560042, Shenyang
Investigational Site Number 3560001, Gūrgaon
Investigational Site Number 1560006, Changchun
Investigational Site Number 1560020, Changchun
Investigational Site Number 1560056, Siping
Investigational Site Number 1560029, Shanghai
Investigational Site Number 1560041, Shanghai
Investigational Site Number 1560053, Shanghai
Investigational Site Number 1560045, Nanjing
Investigational Site Number 1560017, Nanjing
Investigational Site Number 1560031, Nanjing
Investigational Site Number 1560019, Xuzhou
Investigational Site Number 1560016, Jinan
Investigational Site Number 1560002, Tianjin
Investigational Site Number 1560022, Tianjin
Investigational Site Number 1560052, Tianjin
Investigational Site Number 1560048, Hangzhou
Investigational Site Number 1560037, Hangzhou
Investigational Site Number 1560008, Hangzhou
Investigational Site Number 1560055, Wenzhou
Investigational Site Number 1560028, Nanchang
Investigational Site Number 1560030, Fuzhou
Investigational Site Number 3560013, Surat
Investigational Site Number 1560023, Changsha
Investigational Site Number 3560005, Pune
Investigational Site Number 3560011, Pune
Investigational Site Number 1560003, Wuhan
Investigational Site Number 3560007, Nagpur
Investigational Site Number 3560004, Nagpur
Investigational Site Number 3560008, Nagpur
Investigational Site Number 3560016, Nagpur
Investigational Site Number 1560005, Guangzhou
Investigational Site Number 1560040, Guangzhou
Investigational Site Number 1560025, Guangzhou
Investigational Site Number 1560036, Shenzhen
Investigational Site Number 3560012, Vijaywada
Investigational Site Number 3560015, Vijayawada
Investigational Site Number 1560057, Zhanjiang
Investigational Site Number 1560035, Nanning
Investigational Site Number 3560020, Mangalore
Investigational Site Number 3560003, Hubli
Investigational Site Number 3560017, Belagavi
Investigational Site Number 3560010, Kolkata
Investigational Site Number 3560019, Kolkata
Investigational Site Number 1560004, Xi'an
Investigational Site Number 1560044, Lanzhou
Investigational Site Number 1560054, Yinchuan
Investigational Site Number 1560014, Hohhot
Investigational Site Number 1560021, Taiyuan
Investigational Site Number 3560006, Mumbai
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY